Answers are grounded in this paper and cite their sources.
In Vitro characterization showed improved pharmacokinetics and reduced IC50 of ursolic acid delivery in leishmaniasis models, suggesting effective treatment formulation.
Ursolic acid (UA), a natural triterpene, demonstrated promising activity against visceral leishmaniasis (VL); however, its clinical use is limited by poor aqueous solubility (< 5.64 µg/mL), low permeability, hindered oral bioavailability (< 3%), and extensive first-pass metabolism. Hence, hyaluronic acid-coated ursolic acid-bearing liposomes (HA-UA-Lips) were formulated using the thin-film hydration method integrated with Box-Behnken Design (BBD). HA-UA-Lips displayed a vesicle size of 200.2 ± 5.2 nm, PDI of 0.164 ± 0.041, and zeta potential of -21.39 ± 0.27 mV. The surface topography analysis confirmed spherical shape and uniform dispersion of vesicles. Additionally, HA-UA-Lips indicated a significant ( P < 0.0001) sustained release of drug after 72 h (70.4 ± 1.68%) as compared to ursolic acid-loaded liposomes (UA-Lips; 87.4 ± 2.61%). The IC 50 of HA-UA-Lips was calculated to be 0.6316 ± 0.0004 µg/mL, which was notably declined ( P < 0.0001) as compared to UA (22.0 ± 0.35 µg/mL) and blank liposomes (Blk-Lips; 36.205 ± 0.745-µg/mL), respectively, in L. donovani -infected murine macrophage cell line J774A.1. The C6-HA-UA-Lips (Coumarin-6-dye-loaded hyaluronic acid-coated ursolic acid bearing liposomes) further demonstrated augmented uptake in RAW264.7 cells compared to C6-UA-Lips (Coumarin-6-dye-loaded ursolic acid bearing liposomes), which probably followed the receptor-mediated endocytosis pathway through extracellular CD44 receptors, enhancing site-specific accumulation. HA-UA-Lips showed significantly improved pharmacokinetics over UA, with 2.6, 4.27, 4.75, and 2.85 fold increases in t 1/2 ( P < 0.01), AUC 0−∞ ( P < 0.0001), AUC 0−t ( P < 0.0001), and MRT ( P < 0.05), respectively, compared to UA. In conclusion, HA-UA-Lips are a novel vesicular drug delivery cargo that should be further tested in a validated preclinical model of VL under stringent in vitro and in vivo parameters for translational research.
No takes yet. Share an insight, caveat, or question.
Gollapalli et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: